Novo Nordisk pared its forecast for a fourth time this year, citing lower-than-anticipated sales of its blockbuster drugs Wegovy and Ozempic. The Danish drugmaker is struggling to compete with Eli Lilly in the growing market for obesity medicines. Bloomberg's Sara Sjolin reports.
View Comments
Novo Cuts Outlook Citing Lower Wegovy, Ozempic Sales
Published 4 days ago
Nov 5, 2025 at 7:07 AM
Negative
Auto